CONNECT Frontiers in Science & Technology: Using Stem Cells to Cure Diabetes
When
Nov 17, 2009 12:00 pm - 1:30 pm (Tuesday)
Where
What
Using Stem Cells to Cure Diabetes
Presented By
E. Edward Baetge, Ph.D.
Senior Vice President & Chief Scientific Officer
Novocell
Program Overview:
Type 1 Diabetes, also known as ju...
Improve this event listing
These people love this event
Start the conversation
Event details: CONNECT Frontiers in Science & Technology: Using Stem Cel...
Description
Using Stem Cells to Cure Diabetes
Presented By
E. Edward Baetge, Ph.D.
Senior Vice President & Chief Scientific Officer
Novocell
Program Overview:
Type 1 Diabetes, also known as juvenile-onset diabetes, affects nearly 3 million Americans, with more than 15,000 children being diagnosed each year. It is the single most costly chronic disease, and in 2007, accounted for $174 billion in health-care costs in the U.S. There is no cure for Type 1 Diabetes, and for decades researchers have been searching for ways to replace the insulin-producing cells of the pancreas that are destroyed by a patient's own faulty immune system.
Recent breakthroughs in this field have led Dr. Baetge, and his team at Novocell, to develop and patent an innovative stem cell therapy to produce functional pancreatic, insulin-producing cells using human embryonic stem cells. This therapy is being designed to be injected into the bodies of diabetics to replace cells that no longer produce insulin. He feels their methods of employing stem cells as a renewable source of cell replacement therapy could lead to the first widespread treatment for diabetes. In addition, his team has published very favorable results using this therapy, where they were able to stop diabetes when the cells were implanted in mice.
However, the development of a replacement cell therapy product will entail more than just a renewable pancreatic cell source. Both the scale up and delivery of this product will require critical elements, and the incorporation of these additional elements will provide the basis to conduct clinical trials in patients with diabetes.
Novocell is the Recipient of a Disease Team Award for $20 Million from the California Institute for Regenerative Medicine to Develop a Stem Cell Therapy for the Treatment of Diabetes
Who Should Attend
Scientists, engineers, physicians, healthcare leaders, venture capitalists, technology and life sciences professionals, services providers, and business leaders.
About the Presenter
E. Edward Baetge, Ph.D., is currently Senior Vice President and Chief Scientific Officer of Novocell formed by the merger of CyThera and BresaGen Inc. in 2004. He was recruited to CyThera as Chief Scientific Officer in 2001 to head its then emerging human embryonic stem cell program. Prior to joining CyThera, Dr. Baetge held the position of Chief Scientific Officer at Modex Therapeutics Ltd from 1997-2001., in Lausanne, Switzerland, which developed one of the first autologous adult stem cell products for the treatment of chronic skin ulcers. Before Modex, Dr. Baetge held management positions at CytoTherapeutics from 1992-1997 and at Bristol-Myers Squibb from 1987-1992 . He holds a Ph.D. in molecular neurobiology from Cornell University and completed postdoctoral work at Cornell University and the Howard Hughes Medical Institute. Dr. Baetge has published extensively in the field of cell therapy and has produced a number of cell technology patents.
Contact: Bethany Kraynack
Email: bkraynack@connect.org
Agenda:
12:00 pm Registration, Lunch & Networking
12:20 pm CONNECT Welcome, Sponsor Introduction
12:25 pm Sponsor Welcome, Speaker Introduction
12:30 pm Speaker Presentation
1:15 pm Q & A
1:30 pm Evaluations & Close
Presented By
E. Edward Baetge, Ph.D.
Senior Vice President & Chief Scientific Officer
Novocell
Program Overview:
Type 1 Diabetes, also known as juvenile-onset diabetes, affects nearly 3 million Americans, with more than 15,000 children being diagnosed each year. It is the single most costly chronic disease, and in 2007, accounted for $174 billion in health-care costs in the U.S. There is no cure for Type 1 Diabetes, and for decades researchers have been searching for ways to replace the insulin-producing cells of the pancreas that are destroyed by a patient's own faulty immune system.
Recent breakthroughs in this field have led Dr. Baetge, and his team at Novocell, to develop and patent an innovative stem cell therapy to produce functional pancreatic, insulin-producing cells using human embryonic stem cells. This therapy is being designed to be injected into the bodies of diabetics to replace cells that no longer produce insulin. He feels their methods of employing stem cells as a renewable source of cell replacement therapy could lead to the first widespread treatment for diabetes. In addition, his team has published very favorable results using this therapy, where they were able to stop diabetes when the cells were implanted in mice.
However, the development of a replacement cell therapy product will entail more than just a renewable pancreatic cell source. Both the scale up and delivery of this product will require critical elements, and the incorporation of these additional elements will provide the basis to conduct clinical trials in patients with diabetes.
Novocell is the Recipient of a Disease Team Award for $20 Million from the California Institute for Regenerative Medicine to Develop a Stem Cell Therapy for the Treatment of Diabetes
Who Should Attend
Scientists, engineers, physicians, healthcare leaders, venture capitalists, technology and life sciences professionals, services providers, and business leaders.
About the Presenter
E. Edward Baetge, Ph.D., is currently Senior Vice President and Chief Scientific Officer of Novocell formed by the merger of CyThera and BresaGen Inc. in 2004. He was recruited to CyThera as Chief Scientific Officer in 2001 to head its then emerging human embryonic stem cell program. Prior to joining CyThera, Dr. Baetge held the position of Chief Scientific Officer at Modex Therapeutics Ltd from 1997-2001., in Lausanne, Switzerland, which developed one of the first autologous adult stem cell products for the treatment of chronic skin ulcers. Before Modex, Dr. Baetge held management positions at CytoTherapeutics from 1992-1997 and at Bristol-Myers Squibb from 1987-1992 . He holds a Ph.D. in molecular neurobiology from Cornell University and completed postdoctoral work at Cornell University and the Howard Hughes Medical Institute. Dr. Baetge has published extensively in the field of cell therapy and has produced a number of cell technology patents.
Contact: Bethany Kraynack
Email: bkraynack@connect.org
Agenda:
12:00 pm Registration, Lunch & Networking
12:20 pm CONNECT Welcome, Sponsor Introduction
12:25 pm Sponsor Welcome, Speaker Introduction
12:30 pm Speaker Presentation
1:15 pm Q & A
1:30 pm Evaluations & Close
Cost
Payment required. Fees: CONNECT Members: $15 Non-Members: $25 Students: $10 At the Door $35Post a Countdown Widget
Countdown to this event with your own widget! You can customize it and post one on your website, MySpace page or blog.
On the MySpace bulletin board page click "Post Bulletin".
Paste code into the Body section and add a Subject to your bulletin.
Then click "Post" and you will be brought to the confirmation page.
Click "Post Bulletin" on the confirmation page and you're done!
Leave a comment after signing in or joining.